Assessment of algorithms for identifying patients with triple-class refractory multiple myeloma using real-world data

References

• Madduri D, Hagiwara M, Parikh K, et al. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA. Future Oncol. 2021;17(5):503–515. doi: 10.2217/fon-2020-1003.
   PubMed Web of Science ®Google Scholar
• Bal S, Malek E, Kansagra A, et al. Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. Leukemia. 2022;36(3):877–880. doi: 10.1038/s41375-021-01471-3.
   PubMed Web of Science ®Google Scholar
• Nooka AK, Kastritis E, Dimopoulos MA, et al. Treatment options for relapsed and refractory multiple myeloma. Blood. 2015;125(20):3085–3099. doi: 10.1182/blood-2014-11-568923.
   PubMed Web of Science ®Google Scholar
• Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):1–7. doi: 10.1016/j.clml.2019.09.621.
   PubMed Web of Science ®Google Scholar
• Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266–2275. doi: 10.1038/s41375-019-0435-7.
   PubMed Web of Science ®Google Scholar
• Lee HC, Ramasamy K, Weisel K, et al. Treatment patterns, survival, quality of life, and healthcare resource use among patients with triple-class refractory multiple myeloma in US clinical practice: findings from the Connect MM Disease Registry. Clin Lymphoma Myeloma Leuk. 2023;23(2):112–122. doi: 10.1016/j.clml.2022.11.008.
   PubMed Web of Science ®Google Scholar
• Kumar S, Baizer L, Callander NS, et al. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer J. 2022;12(6):98. doi: 10.1038/s41408-022-00695-5.
   PubMed Web of Science ®Google Scholar
• Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346. doi: 10.1016/S1470-2045(16)30206-6.
   PubMed Web of Science ®Google Scholar
• Foster RB, Tromanhauser M, Gayer C, et al. Approximating International Myeloma Working Group uniform response criteria to derive response for multiple myeloma (MM) patients using data from electronic health records (EHR). Blood. 2019;134(Supplement_1):4727–4727. Abstract 4727, doi: 10.1182/blood-2019-127181.
   Google Scholar
• Lane D, Norden AD, Belli AJ, et al. Assessing real-world clinical response in patients with multiple myeloma (MM): a survey of the literature. J Clin Oncol. 2020;38(15_suppl):e19260–e19260. doi: 10.1200/JCO.2020.38.15_suppl.e19260.
   Web of Science ®Google Scholar
• COTA Healthcare [Internet]. Life sciences. [cited 2023 Aug 28] Available from: https://cotahealthcare.com/life-sciences/.
   Google Scholar
• COTA Healthcare. Multiple myeloma real-world evidence. New York, NY: COTA Healthcare; 2022.
   Google Scholar
• Goldman-Mazur S, Visram A, Kapoor P, et al. Outcomes after biochemical or clinical progression in patients with multiple myeloma. Blood Adv. 2023;7(6):909–917. doi: 10.1182/bloodadvances.2022007082.
   PubMed Web of Science ®Google Scholar
• Chakraborty R, Liu HD, Rybicki L, et al. Progression with clinical features is associated with worse subsequent survival in multiple myeloma. Am J Hematol. 2019;94(4):439–445. doi: 10.1002/ajh.25415.
   PubMed Web of Science ®Google Scholar
• Soyer N, Patır P, Uysal A, et al. Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: a real-life experience. Turk J Med Sci. 2018;48(4):777–785. doi: 10.3906/sag-1712-160.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Kuroda J, Fuchida S, et al. Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma. Int J Hematol. 2015;101(1):37–45. doi: 10.1007/s12185-014-1696-6.
   PubMed Web of Science ®Google Scholar
• Jethava YS, Mitchell A, Epstein J, et al. Adverse metaphase cytogenetics can be overcome by adding bortezomib and thalidomide to fractionated melphalan transplants. Clin Cancer Res. 2017;23(11):2665–2672. doi: 10.1158/1078-0432.CCR-15-2620.
   PubMed Web of Science ®Google Scholar
• Moreau P, Stewart KA, Dimopoulos M, et al. Once-weekly (70 mg/m2) vs twice-weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: a post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials. Cancer Med. 2020;9(9):2989–2996. doi: 10.1002/cam4.2945.
   PubMed Web of Science ®Google Scholar
• Sharkey MM, McKavanagh D, Walpole E, et al. Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting. Int J Clin Pharm. 2017;39(4):836–843. doi: 10.1007/s11096-017-0480-0.
   PubMed Web of Science ®Google Scholar
• Jelínek T, Maisnar V, Pour L, et al. Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients. Curr Med Res Opin. 2018;34(5):775–783. doi: 10.1080/03007995.2017.1410121.
   PubMed Web of Science ®Google Scholar
• Sun C, Ye JN, Mao JJ, et al. Impact of extended treatment interval on the prognosis of multiple myeloma patients: a retrospective study. Oncol Res Treat. 2020;43(11):592–604. doi: 10.1159/000508451.
   PubMed Web of Science ®Google Scholar
• Smetana J, Berankova K, Zaoralova R, et al. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib. Clin Lymphoma Myeloma Leuk. 2013;13(2):123–130. doi: 10.1016/j.clml.2012.11.012.
   PubMed Web of Science ®Google Scholar
• Rocchi S, Tacchetti P, Pantani L, et al. A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma. Hematol Oncol. 2021;39(1):41–50. doi: 10.1002/hon.2820.
   PubMed Web of Science ®Google Scholar
• Wang H, Hu WM, Xia ZJ, et al. High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens. J Cancer. 2019;10(14):3239–3245. doi: 10.7150/jca.30102.
   PubMed Web of Science ®Google Scholar
• Varga G, Dávid Tóth A, Réka Szita V, et al. Beneficial effect of lenalidomide-dexamethason treatment in relapsed/refractory multiple myeloma patients: results of real-life data from 11 Hungarian centers. Pathol Oncol Res. 2021;27:613264. doi: 10.3389/pore.2021.613264.
   PubMed Web of Science ®Google Scholar
• Oka S, Ono K, Nohgawa M. Clinical effects of CD33 and MPC-1 on the prognosis of multiple myeloma treated with bortezomib. Leuk Lymphoma. 2019;60(9):2152–2157. doi: 10.1080/10428194.2019.1574003.
   PubMed Web of Science ®Google Scholar
• Matsumura-Kimoto Y, Kuroda J, Kaneko H, et al. Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum. Int J Hematol. 2018;107(5):541–550. doi: 10.1007/s12185-018-2416-4.
   PubMed Web of Science ®Google Scholar
• Goel U, Charalampous C, Kapoor P, et al. Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma. Blood Cancer J. 2023;13(1):11. doi: 10.1038/s41408-023-00785-y.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Diels J, Ito T, et al. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: an adjusted treatment comparison. Am J Hematol. 2017;92(8):E146–E152. doi: 10.1002/ajh.24781.
   PubMed Web of Science ®Google Scholar
• Usnarska-Zubkiewicz L, Debski J, Butrym A, et al. Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients—report of the Polish Myeloma Group. Leuk Res. 2016;40:90–99. doi: 10.1016/j.leukres.2015.11.005.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31(11):2443–2448. doi: 10.1038/leu.2017.138.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Lin Y, Goldschmidt H, et al. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer J. 2021;11(6):116. doi: 10.1038/s41408-021-00507-2.
   PubMed Web of Science ®Google Scholar
• Dhanasiri S, Hollier-Hann G, Stothard C, et al. Treatment patterns and outcomes in triple-class exposed patients with relapsed and refractory multiple myeloma: findings from the multinational ITEMISE study. Clin Ther. 2021;43(11):1983–1996.e3. doi: 10.1016/j.clinthera.2021.09.013.
   PubMed Web of Science ®Google Scholar
• Mohty M, Terpos E, Mateos MV, et al. Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study. Clin Lymphoma Myeloma Leuk. 2018;18(10):e401–e419. doi: 10.1016/j.clml.2018.06.018.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Richardson P, San Miguel JF. Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood [Internet]. 2015; Aug 13 [cited 2023 Sep 15];126(7):921–922. https://pubmed.ncbi.nlm.nih.gov/26272048/ doi: 10.1182/blood-2015-05-647636.
   Google Scholar